During a panel discussion held at DIA Global 2024, industry experts discussed how AI and real-world data (RWD) are accelerating drug development.
LEARN MORE about how curated clinical trial datasets can be used by AI to transform medicine
LEARN MORE about how curated clinical trial datasets can be used by AI to transform medicine
This cutting-edge platform provides secure access to anonymized, local-level data encompassing diagnosis, treatment, demographics, and more across England. By utilizing this platform, healthcare stakeholders can make informed strategic decisions, optimize resource allocation, enhance treatment strategies, and improve care coordination and outcomes.
The first Real-World Data (RWD) platform offering primary care activity data, Vantage utilizes a panel dataset sourced from EMIS, SystmOne, and Vision, covering England. With more than 15.6 million patients added to the primary care panel dataset since 2019, it is currently the fastest-growing GP-provided source.
For more information on Primary Care Activity Data and to request a demo of CorEvitas’ Vantage platform, please visit CorEvitas’ Vantage Primary Care Activity Data
Our groundbreaking research is referenced by the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP) Drug Safety Journal.
The WHO publication titled “Pregnancy Exposure Registries in Low- and Middle-Income Countries (LMICs)*” sheds light on the vital role of pregnancy exposure registries in LMICs. According to the WHO publication, pregnancy registries play a pivotal role in monitoring the safety and outcomes of medications, vaccines, and other exposures during pregnancy, especially in regions where such data are scarce. The research conducted by CorEvitas’ pregnancy registry has significantly contributed to filling this critical gap in knowledge.
Findings from our pregnancy registry studies have been acknowledged in the Drug Safety Journal by the International Society of Pharmacovigilance (ISoP). The manuscript titled “The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations,” published in the journal, assesses the relative risk of obstetric, neonatal, and infant outcomes associated with the use of drugs specifically indicated for the treatment of COVID-19 compared with other drug treatment strategies. These data provide valuable insights about COVID-19 treatment during pregnancy for healthcare professionals, policymakers, and researchers.
The acknowledgement of these data in prestigious publications reaffirms the importance of pregnancy registry studies in facilitating evidence-based decision-making to improve maternal and fetal health outcomes worldwide.
For more information about CorEvitas’ pregnancy registries, click here
Read the abstract: The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations
Download the WHO publication: Pregnancy Exposure Registries in Low- and Middle-Income Countries (LMICs)*
*Landscape analysis of pregnancy exposure registries in low- and middle-income countries. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).”
We are pleased to announce the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease.
Read the press release, here.
To find out more about the GPP registry, including some information on some of the variables we collect, visit corevitas.com/gpp-generalized-pustular-psoriasis-registry/